These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1059 related items for PubMed ID: 26815314

  • 21. Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis.
    Siddiqui MS, Van Natta ML, Connelly MA, Vuppalanchi R, Neuschwander-Tetri BA, Tonascia J, Guy C, Loomba R, Dasarathy S, Wattacheril J, Chalasani N, Sanyal AJ, NASH CRN.
    J Hepatol; 2020 Jan; 72(1):25-33. PubMed ID: 31634532
    [Abstract] [Full Text] [Related]

  • 22. Liver fibrosis markers of nonalcoholic steatohepatitis.
    Enomoto H, Bando Y, Nakamura H, Nishiguchi S, Koga M.
    World J Gastroenterol; 2015 Jun 28; 21(24):7427-35. PubMed ID: 26139988
    [Abstract] [Full Text] [Related]

  • 23. Ultrasonographic Nonalcoholic Fatty Pancreas Is Associated with Advanced Fibrosis in NAFLD: A Retrospective Analysis.
    Rosenblatt R, Mehta A, Snell D, Hissong E, Kierans AS, Kumar S.
    Dig Dis Sci; 2019 Jan 28; 64(1):262-268. PubMed ID: 30269271
    [Abstract] [Full Text] [Related]

  • 24. Multicenter Validation Study of a Diagnostic Algorithm to Detect NASH and Fibrosis in NAFLD Patients With Low NAFLD Fibrosis Score or Liver Stiffness.
    Liebig S, Stoeckmann N, Geier A, Rau M, Schattenberg JM, Bahr MJ, Manns MP, Jaeckel E, Schulze-Osthoff K, Bantel H.
    Clin Transl Gastroenterol; 2019 Aug 28; 10(8):e00066. PubMed ID: 31397685
    [Abstract] [Full Text] [Related]

  • 25. Biopsy rate and nonalcoholic steatohepatitis (NASH) in patients with nonalcoholic fatty liver disease (NAFLD).
    Gerhardt F, Petroff D, Blank V, Böhlig A, van Bömmel F, Wittekind C, Berg T, Karlas T, Wiegand J.
    Scand J Gastroenterol; 2020 Jun 28; 55(6):706-711. PubMed ID: 32476514
    [Abstract] [Full Text] [Related]

  • 26. Histopathological stages of nonalcoholic fatty liver disease in type 2 diabetes: prevalences and correlated factors.
    Leite NC, Villela-Nogueira CA, Pannain VL, Bottino AC, Rezende GF, Cardoso CR, Salles GF.
    Liver Int; 2011 May 28; 31(5):700-6. PubMed ID: 21457442
    [Abstract] [Full Text] [Related]

  • 27. Lipoprotein subclass metabolism in nonalcoholic steatohepatitis.
    Männistö VT, Simonen M, Soininen P, Tiainen M, Kangas AJ, Kaminska D, Venesmaa S, Käkelä P, Kärjä V, Gylling H, Ala-Korpela M, Pihlajamäki J.
    J Lipid Res; 2014 Dec 28; 55(12):2676-84. PubMed ID: 25344588
    [Abstract] [Full Text] [Related]

  • 28. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y, Fukusato T.
    World J Gastroenterol; 2014 Nov 14; 20(42):15539-48. PubMed ID: 25400438
    [Abstract] [Full Text] [Related]

  • 29. The macrophage activation marker sCD163 is associated with morphological disease stages in patients with non-alcoholic fatty liver disease.
    Kazankov K, Barrera F, Møller HJ, Rosso C, Bugianesi E, David E, Younes R, Esmaili S, Eslam M, McLeod D, Bibby BM, Vilstrup H, George J, Grønbaek H.
    Liver Int; 2016 Oct 14; 36(10):1549-57. PubMed ID: 27102725
    [Abstract] [Full Text] [Related]

  • 30. Features of nonalcoholic steatohepatitis in severely obese children and adolescents undergoing sleeve gastrectomy.
    Alqahtani A, Elahmedi M, Alswat K, Arafah M, Fagih M, Lee J.
    Surg Obes Relat Dis; 2017 Sep 14; 13(9):1599-1609. PubMed ID: 28600116
    [Abstract] [Full Text] [Related]

  • 31. Prevalence and risk factors for biopsy-proven non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in a prospective cohort of adult patients with gallstones.
    García-Monzón C, Vargas-Castrillón J, Porrero JL, Alonso MT, Bonachía O, Castillo MJ, Marcos A, Quirós E, Ramos B, Sánchez-Cabezudo C, Villar S, Sáez A, Rodríguez de Cía J, del Pozo E, Vega-Piris L, Soto-Fernández S, Lo Iacono O, Miquilena-Colina ME.
    Liver Int; 2015 Aug 14; 35(8):1983-91. PubMed ID: 25708133
    [Abstract] [Full Text] [Related]

  • 32. Nonalcoholic fatty liver disease: biomarkers as diagnostic tools for liver damage assessment in adult patients from Argentina.
    Valva P, Rios D, Casciato P, Gadano A, Galdame O, Mullen E, Bertot G, de Matteo E, Preciado MV.
    Eur J Gastroenterol Hepatol; 2018 Jun 14; 30(6):637-644. PubMed ID: 29384795
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Diagnosis and Evaluation of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Including Noninvasive Biomarkers and Transient Elastography.
    Tsai E, Lee TP.
    Clin Liver Dis; 2018 Feb 14; 22(1):73-92. PubMed ID: 29128062
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Lipoprotein Profiles in Class III Obese Caucasian and African American Women with Nonalcoholic Fatty Liver Disease.
    Garcia AE, Kasim N, Tamboli RA, Gonzalez RS, Antoun J, Eckert EA, Marks-Shulman PA, Dunn J, Wattacheril J, Wallen T, Abumrad NN, Flynn CR.
    PLoS One; 2015 Feb 14; 10(11):e0142676. PubMed ID: 26599819
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis.
    Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, Torres-Gonzalez A, Gra-Oramas B, Gonzalez-Fabian L, Friedman SL, Diago M, Romero-Gomez M.
    Gastroenterology; 2015 Aug 14; 149(2):367-78.e5; quiz e14-5. PubMed ID: 25865049
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 53.